|
1
|
Siegel RL, Fedewa SA, Miller KD,
Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2015. CA Cancer J Clin.
65:457–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Napetschnig J and Wu H: Molecular basis of
NF-κB signaling. Annu Rev Biophys. 42:443–468. 2013. View Article : Google Scholar :
|
|
3
|
Weih F and Caamaño J: Regulation of
secondary lymphoid organ development by the nuclear factor-kappaB
signal transduction pathway. Immunol Rev. 195:91–105. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perkins ND: The diverse and complex roles
of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132.
2012.PubMed/NCBI
|
|
5
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suh J and Rabson AB: NF-kappaB activation
in human prostate cancer: Important mediator or epiphenomenon? J
Cell Biochem. 91:100–117. 2004. View Article : Google Scholar
|
|
7
|
Lessard L, Bégin LR, Gleave ME, Mes-Masson
AM and Saad F: Nuclear localisation of nuclear factor-kappaB
transcription factors in prostate cancer: An immunohistochemical
study. Br J Cancer. 93:1019–1023. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo F, Kang S, Zhou P, Guo L, Ma L and Hou
J: Maspin expression is regulated by the non-canonical NF-κB
subunit in androgen-insensitive prostate cancer cell lines. Mol
Immunol. 49:8–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lessard L, Saad F, Le Page C, Diallo JS,
Péant B, Delvoye N and Mes-Masson AM: NF-kappaB2 processing and p52
nuclear accumulation after androgenic stimulation of LNCaP prostate
cancer cells. Cell Signal. 19:1093–1100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Holley AK, Xu Y, St Clair DK and St Clair
WH: RelB regulates manganese superoxide dismutase gene and
resistance to ionizing radiation of prostate cancer cells. Ann NY
Acad Sci. 1201:129–136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Y, Fang F, St Clair DK, Josson S,
Sompol P, Spasojevic I and St Clair WH: Suppression of
RelB-mediated manganese superoxide dismutase expression reveals a
primary mechanism for radiosensitization effect of
1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol
Cancer Ther. 6:2048–2056. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mineva ND, Wang X, Yang S, Ying H, Xiao
ZX, Holick MF and Sonenshein GE: Inhibition of RelB by
1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer
cells to radiation. J Cell Physiol. 220:593–599. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shukla S, Kanwal R, Shankar E, Datt M,
Chance MR, Fu P, MacLennan GT and Gupta S: Apigenin blocks IKKα
activation and suppresses prostate cancer progression. Oncotarget.
6:31216–31232. 2015.PubMed/NCBI
|
|
14
|
Luo JL, Tan W, Ricono JM, Korchynskyi O,
Zhang M, Gonias SL, Cheresh DA and Karin M: Nuclear
cytokine-activated IKKalpha controls prostate cancer metastasis by
repressing Maspin. Nature. 446:690–694. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo F, Sun A, Wang W, He J, Hou J, Zhou P
and Chen Z: TRAF1 is involved in the classical NF-kappaB activation
and CD30-induced alternative activity in Hodgkin's lymphoma cells.
Mol Immunol. 46:2441–2448. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu J, Zhou P, Wang W, Sun A and Guo F:
RelB, together with RelA, sustains cell survival and confers
proteasome inhibitor sensitivity of chronic lymphocytic leukemia
cells from bone marrow. J Mol Med Berl. 92:77–92. 2014. View Article : Google Scholar
|
|
17
|
Ranuncolo SM, Pittaluga S, Evbuomwan MO,
Jaffe ES and Lewis BA: Hodgkin lymphoma requires stabilized NIK and
constitutive RelB expression for survival. Blood. 120:3756–3763.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu Y, Josson S, Fang F, Oberley TD, St
Clair DK, Wan XS, Sun Y, Bakthavatchalu V, Muthuswamy A and St
Clair WH: RelB enhances prostate cancer growth: Implications for
the role of the nuclear factor-kappaB alternative pathway in
tumorigenicity. Cancer Res. 69:3267–3271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu Y, Fang F, St Clair DK and St Clair WH:
Inverse relationship between PSA and IL-8 in prostate cancer: An
insight into a NF-κB-mediated mechanism. PLoS One. 7:e329052012.
View Article : Google Scholar
|
|
20
|
Cormier F, Monjanel H, Fabre C, Billot K,
Sapharikas E, Chereau F, Bordereaux D, Molina TJ, Avet-Loiseau H
and Baud V: Frequent engagement of RelB activation is critical for
cell survival in multiple myeloma. PLoS One. 8:e591272013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou J, Hualong Q, Zhou P and Guo F:
Different maspin functions in the lung adenocarcinoma A549 and
SPC-A1 cell lines. Int J Mol Med. 36:1440–1448. 2015.PubMed/NCBI
|
|
22
|
Wang X, Belguise K, O'Neill CF,
Sánchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C,
Trinkaus-Randall V, et al: RelB NF-kappaB represses estrogen
receptor alpha expression via induction of the zinc finger protein
Blimp1. Mol Cell Biol. 29:3832–3844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu Z, Sato S, Trackman PC, Kirsch KH and
Sonenshein GE: Blimp1 activation by AP-1 in human lung cancer cells
promotes a migratory phenotype and is inhibited by the lysyl
oxidase propeptide. PLoS One. 7:e332872012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang X, Belguise K, Kersual N, Kirsch KH,
Mineva ND, Galtier F, Chalbos D and Sonenshein GE: Oestrogen
signalling inhibits invasive phenotype by repressing RelB and its
target BCL2. Nat Cell Biol. 9:470–478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Peeters MC, Fokkelman M, Boogaard B,
Egerod KL, van de Water B, IJzerman AP and Schwartz TW: The
adhesion G protein-coupled receptor G2 (ADGRG2/GPR64)
constitutively activates SRE and NFκB and is involved in cell
adhesion and migration. Cell Signal. 27:2579–2588. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Authier H, Billot K, Derudder E,
Bordereaux D, Rivière P, Rodrigues-Ferreira S, Nahmias C and Baud
V: IKK phosphorylates RelB to modulate its promoter specificity and
promote fibroblast migration downstream of TNF receptors. Proc Natl
Acad Sci USA. 111:14794–14799. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang XM, Li J, Yan MX, Liu L, Jia DS, Geng
Q, Lin HC, He XH, Li JJ and Yao M: Integrative analyses identify
osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for
lung cancer. PLoS One. 8:e557142013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee YC, Jin JK, Cheng CJ, Huang CF, Song
JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, et al: Targeting
constitutively activated β1 integrins inhibits prostate cancer
metastasis. Mol Cancer Res. 11:405–417. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ravenhill L, Wagstaff L, Edwards DR, Ellis
V and Bass R: G-helix of maspin mediates effects on cell migration
and adhesion. J Biol Chem. 285:36285–36292. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saito T, Sasaki CY, Rezanka LJ, Ghosh P
and Longo DL: p52-independent nuclear translocation of RelB
promotes LPS-induced attachment. Biochem Biophys Res Commun.
391:235–241. 2010. View Article : Google Scholar :
|
|
31
|
Xie BX, Zhang H, Yu L, Wang J, Pang B, Wu
RQ, Qian XL, Li SH, Shi QG, Wang LL, et al: The radiation response
of androgen-refractory prostate cancer cell line C4-2 derived from
androgen-sensitive cell line LNCaP. Asian J Androl. 12:405–414.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu Y, Fang F, St Clair DK, Sompol P,
Josson S and St Clair WH: SN52, a novel nuclear factor-kappaB
inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes
prostate cancer cells to ionizing radiation. Mol Cancer Ther.
7:2367–2376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu L, Zhu B, Yang L, Zhao X, Jiang H and
Ma F: RelB regulates Bcl-xL expression and the irradiation-induced
apoptosis of murine prostate cancer cells. Biomed Rep. 2:354–358.
2014.PubMed/NCBI
|
|
34
|
Harima Y, Harima K, Shikata N, Oka A,
Ohnishi T and Tanaka Y: Bax and Bcl-2 expressions predict response
to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol.
124:503–510. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu Y, Fang F, Sun Y, St Clair DK and St
Clair WH: RelB-dependent differential radiosensitization effect of
STI571 on prostate cancer cells. Mol Cancer Ther. 9:803–812. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Manna S, Singha B, Phyo SA, Gatla HR,
Chang TP, Sanacora S, Ramaswami S and Vancurova I: Proteasome
inhibition by bortezomib increases IL-8 expression in
androgen-independent prostate cancer cells: The role of IKKα. J
Immunol. 191:2837–2846. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Singha B, Gatla HR, Manna S, Chang TP,
Sanacora S, Poltoratsky V, Vancura A and Vancurova I: Proteasome
inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65,
and transcription factor EGR1 to interleukin-8 (IL-8) promoter,
resulting in increased IL-8 production in ovarian cancer cells. J
Biol Chem. 289:2687–2700. 2014. View Article : Google Scholar
|
|
38
|
Garber K: Gene mutation revelation points
to new target for myeloma treatment, studies say. J Natl Cancer
Inst. 99:1362–1364. 2007. View Article : Google Scholar : PubMed/NCBI
|
